Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | LY3300054 + LY3381916 |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
LY3300054 | Lodapolimab | Immune Checkpoint Inhibitor 149 PD-L1/PD-1 antibody 121 | LY3300054 (lodapolimab), is a monoclonal antibody against CD274 (PD-L1) that inhibits binding to the PDCD1 (PD1) receptor, potentially resulting in enhanced anti-tumor immune response (PMID: 29712568). | |
LY3381916 | LY-3381916|LY 3381916 | IDO1 Inhibitor 12 | LY3381916 binds to and inhibits indoleamine 2,3-dioxygenase 1 (IDO1), resulting in decreased conversion of tryptophan to kynurenine and potentially leading to increased activation of immune response against tumor cells (NCI Thesaurus). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT03343613 | Phase I | LY3300054 + LY3381916 LY3381916 | A Study of LY3381916 Alone or in Combination With LY3300054 in Participants With Solid Tumors | Terminated | USA | ITA | FRA | ESP | DNK | BEL | 0 |